MedTrace Logo

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

NCT03215927 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-07

Study results available
· View outcomes & findings →

Summary

A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.

Conditions

Interventions

DRUG

Abatacept

Abatacept 125mg subcutaneous weekly

OTHER

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Rohit Aggarwal, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2022-05-30
Completion
2023-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03215927 on ClinicalTrials.gov